Two Sigma Investments
TVRD

Two Sigma Investments’s Tvardi Therapeutics TVRD Stock Holding History

Two Sigma Investments’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,492
Closed -$45.1K – 5018
2025
Q4 		$45.1K Buy
+10,492
New +$94K ﹤0.01% 3947
2024
Q4 		– Sell
-6,692
Closed -$74.2K – 3556
2024
Q3 		$74.2K Sell
6,692
-368
-5% -$4.31K ﹤0.01% 2928
2024
Q2 		$65.6K Sell
7,060
-662
-9% -$15.8K ﹤0.01% 2863
2024
Q1 		$253K Sell
7,722
-813
-10% -$21.1K ﹤0.01% 2624
2023
Q4 		$228K Buy
8,535
+6,597
+340% +$273K ﹤0.01% 2784
2023
Q3 		$117K Sell
1,938
-4,714
-71% -$442K ﹤0.01% 2728
2023
Q2 		$678K Buy
6,652
+2,104
+46% +$290K ﹤0.01% 2178
2023
Q1 		$804K Buy
+4,548
New +$1.52M ﹤0.01% 1990
2022
Q3 		– Sell
-3,779
Closed -$1.24M – 2901
2022
Q2 		$1.24M Buy
3,779
+111
+3% +$38.9K ﹤0.01% 1447
2022
Q1 		$1.6M Buy
3,668
+1,260
+52% +$517K ﹤0.01% 1460
2021
Q4 		$1.06M Sell
2,408
-1,766
-42% -$887K ﹤0.01% 2518
2021
Q3 		$2.32M Buy
4,174
+2,250
+117% +$1.13M 0.01% 1856
2021
Q2 		$988K Sell
1,924
-10,567
-85% -$6.7M ﹤0.01% 2487
2021
Q1 		$9.76M Buy
12,491
+5,142
+70% +$3.52M 0.03% 711
2020
Q4 		$4M Sell
7,349
-2,421
-25% -$1.27M 0.01% 1055
2020
Q3 		$4.48M Buy
9,770
+3,233
+49% +$1.88M 0.02% 846
2020
Q2 		$4.02M Buy
6,537
+4,803
+277% +$2.65M 0.02% 748
2020
Q1 		$825K Sell
1,734
-1,170
-40% -$636K 0.01% 1562
2019
Q4 		$1.68M Buy
+2,904
New +$2.04M 0.01% 1735
2019
Q1 		– Sell
-3,371
Closed -$1.58M – 3543
2018
Q4 		$1.58M Buy
+3,371
New +$2.17M 0.01% 1374
2016
Q2 		– Sell
-839
Closed -$188K – 3304
2016
Q1 		$188K Sell
839
-274
-25% -$81.8K ﹤0.01% 2602
2015
Q4 		$675K Buy
+1,113
New +$611K ﹤0.01% 1772

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Two Sigma Investments's TVRD Position: Q1 2026 in Review

Two Sigma Investments sold out of Tvardi Therapeutics (TVRD) in Q1 2026, closing a stake of 10,492 shares — an estimated $45.1K sold.

Two Sigma Investments first reported a position in TVRD in Q4 2015 and held it in 22 quarters. The position peaked at $9.76M in Q1 2021. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • Two Sigma Investments reported no remaining Tvardi Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Investments sold 10,492 Tvardi Therapeutics shares in Q1 2026, an estimated $45.1K.
  • Two Sigma Investments first reported a position in Tvardi Therapeutics in Q4 2015 and held it in 22 quarters.
  • Two Sigma Investments's Tvardi Therapeutics position peaked at $9.76M in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.